PortfoliosLab logo
Vivos Therapeutics, Inc. (VVOS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US92859E1082

CUSIP

92859E108

IPO Date

Dec 11, 2020

Highlights

Market Cap

$14.84M

EPS (TTM)

-$2.43

Total Revenue (TTM)

$11.61M

Gross Profit (TTM)

$7.08M

EBITDA (TTM)

-$6.95M

Year Range

$1.91 - $6.28

Target Price

$5.85

Short %

5.43%

Short Ratio

3.72

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Vivos Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%NovemberDecember2025FebruaryMarchApril
-98.79%
49.72%
VVOS (Vivos Therapeutics, Inc.)
Benchmark (^GSPC)

Returns By Period

Vivos Therapeutics, Inc. had a return of -36.83% year-to-date (YTD) and 5.45% in the last 12 months.


VVOS

YTD

-36.83%

1M

-22.35%

6M

1.50%

1Y

5.45%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-6.75%

1M

-5.05%

6M

-5.60%

1Y

8.15%

5Y*

14.14%

10Y*

10.05%

*Annualized

Monthly Returns

The table below presents the monthly returns of VVOS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-7.46%-12.59%-17.87%-4.91%-36.83%
2024-40.76%-21.17%-16.87%-47.62%-17.39%6.22%3.60%17.83%-3.69%-3.45%35.32%25.81%-65.51%
2023171.14%-44.04%-44.10%0.88%11.05%33.51%-42.94%-13.75%-23.51%-33.12%663.24%-49.22%23.78%
20229.78%35.22%-19.76%-35.45%17.34%-36.45%-10.85%6.96%-47.15%10.77%-30.56%-19.60%-82.13%
202110.66%14.83%-11.58%4.67%-22.59%-7.99%-38.99%74.17%-23.19%-10.15%-29.75%-11.76%-61.93%
2020-34.26%-34.26%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of VVOS is 56, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of VVOS is 5656
Overall Rank
The Sharpe Ratio Rank of VVOS is 5353
Sharpe Ratio Rank
The Sortino Ratio Rank of VVOS is 6363
Sortino Ratio Rank
The Omega Ratio Rank of VVOS is 5959
Omega Ratio Rank
The Calmar Ratio Rank of VVOS is 5353
Calmar Ratio Rank
The Martin Ratio Rank of VVOS is 5353
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Vivos Therapeutics, Inc. (VVOS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The chart of Sharpe ratio for VVOS, currently valued at 0.03, compared to the broader market-2.00-1.000.001.002.003.00
VVOS: 0.03
^GSPC: 0.49
The chart of Sortino ratio for VVOS, currently valued at 0.88, compared to the broader market-6.00-4.00-2.000.002.004.00
VVOS: 0.88
^GSPC: 0.81
The chart of Omega ratio for VVOS, currently valued at 1.10, compared to the broader market0.501.001.502.00
VVOS: 1.10
^GSPC: 1.12
The chart of Calmar ratio for VVOS, currently valued at 0.03, compared to the broader market0.001.002.003.004.005.00
VVOS: 0.03
^GSPC: 0.50
The chart of Martin ratio for VVOS, currently valued at 0.09, compared to the broader market-10.00-5.000.005.0010.0015.0020.00
VVOS: 0.09
^GSPC: 2.07

The current Vivos Therapeutics, Inc. Sharpe ratio is 0.03. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Vivos Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2025FebruaryMarchApril
0.03
0.49
VVOS (Vivos Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Vivos Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2025FebruaryMarchApril
-98.88%
-10.73%
VVOS (Vivos Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Vivos Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Vivos Therapeutics, Inc. was 99.19%, occurring on May 30, 2024. The portfolio has not yet recovered.

The current Vivos Therapeutics, Inc. drawdown is 98.88%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.19%Apr 7, 2021793May 30, 2024
-35.13%Dec 18, 20209Dec 31, 202063Apr 5, 202172
-24.58%Dec 14, 20203Dec 16, 20201Dec 17, 20204

Volatility

Volatility Chart

The current Vivos Therapeutics, Inc. volatility is 28.12%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%NovemberDecember2025FebruaryMarchApril
28.12%
14.23%
VVOS (Vivos Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Vivos Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items